MEK Inhibitor Shrinks Painful Neurofibromas |
Journal Updates
eMediNexus Coverage from: 
MEK Inhibitor Shrinks Painful Neurofibromas

0 Read Comments                

Over half of children with inoperable plexiform neurofibromas responded to the mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor selumetinib, with responses proving durable in most cases, suggested a phase II trial.

Single-agent selumetinib yielded objective responses in 35 of 50 patients, and 28 of the responses lasted for at least a year. The treatment also produced durable improvement in patient-reported pain intensity and other patient- and parent-reported functional and quality-of-life (QoL) outcomes, reported researchers in the New England Journal of Medicine.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now